Drug profile · INN
trilostane
MODRASTANE
trilostane (MODRASTANE) is a 3-beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type ii inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — trilostane
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
trilostane (MODRASTANE) is a 3-beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type ii inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
3-beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type II inhibitor
Primary target: 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Frequently asked questions
What is trilostane?
trilostane (MODRASTANE) is a 3-beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type ii inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for trilostane?
MODRASTANE is a marketed brand name for trilostane. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of trilostane?
trilostane has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.